Last reviewed · How we verify
St. John's Wort extract
St. John's Wort extract is a natural product Small molecule drug developed by Cassella-med GmbH & Co. KG. It is currently in Phase 3 development for Mild to moderate depression. Also known as: Jarsin, LI 160.
St. John's Wort extract acts as a natural antidepressant by increasing levels of neurotransmitters like serotonin, dopamine, and norepinephrine in the brain.
St. John's Wort extract has been studied in clinical trials for various conditions, including Hepatitis C, Phobic Disorders, and Skin Recovery in Different Human Skin Damage Models. The exact mechanism of St. John's Wort extract is unknown, but it has been co-administered with other substances, such as Boceprevir, in clinical trials.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | St. John's Wort extract |
|---|---|
| Also known as | Jarsin, LI 160 |
| Sponsor | Cassella-med GmbH & Co. KG |
| Drug class | natural product |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
It inhibits the reuptake of these neurotransmitters, which can help improve mood and alleviate symptoms of depression. Additionally, it may interact with other pathways, such as the inhibition of cytokine production and modulation of neurotrophic factors.
Approved indications
- Mild to moderate depression
Common side effects
- Nausea
- Dizziness
- Dry mouth
Key clinical trials
- THE EFFECT OF ST. JOHN'S WORT OİL APPLİCATİON ON PERIORBITAL EDEMA AND ECCHYMOSİS AFTER RHİNOPLASTY (NA)
- The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature
- St. John's Wort Oil for Wound Healing and Pain After Cesarean Section (NA)
- Effect of St. John's Wort in the Treatment of Recurrent Aphthous Stomatitis (NA)
- Effects of Botanical Microglia Modulators in Gulf War Illness (NA)
- Investigating Orthobiologics After PRP and Photobiomodulation for Knee Osteoarthritis (NA)
- Effect of St. John's Wort Oil on Skin Moisture in Intensive Care Patients (NA)
- The Use of St. John's Wort Oil With Massage in the Perineum During Childbirth (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- St. John's Wort extract CI brief — competitive landscape report
- St. John's Wort extract updates RSS · CI watch RSS
- Cassella-med GmbH & Co. KG portfolio CI
Frequently asked questions about St. John's Wort extract
What is St. John's Wort extract?
How does St. John's Wort extract work?
What is St. John's Wort extract used for?
Who makes St. John's Wort extract?
Is St. John's Wort extract also known as anything else?
What drug class is St. John's Wort extract in?
What development phase is St. John's Wort extract in?
What are the side effects of St. John's Wort extract?
Related
- Drug class: All natural product drugs
- Manufacturer: Cassella-med GmbH & Co. KG — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Mild to moderate depression
- Also known as: Jarsin, LI 160
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing